Fact Sheet

Download Fact Sheet (PDF)

ViroPharma Incorporated
730 Stockton Drive, Exton, PA 19341
Phone: (610) 458-7300, Fax: (610) 458-7380
Website: http://www.viropharma.com

Senior Management

Vincent J. Milano; President and Chief Executive Officer
Colin Broom, M.D.; Vice President and Chief Scientific Officer
Thomas F. Doyle, JD; Vice President, Strategic Initiatives
Robert G. Pietrusko, Pharm.D.; Vice President, Global Regulatory Affairs and Quality
Charles A. Rowland, CPA, MBA; Vice President and Chief Financial Officer
Daniel B. Soland; Vice President and Chief Operating Officer

Board of Directors

Vincent J. Milano, Chairman
Frank Baldino, Jr., Ph.D.; Chief Executive Officer and Chairman of the Board of Directors of Cephalon Inc.
Paul A. Brooke; Managing Director and Co-Founder of venBio; managing member, PMSV Holdings LLC.
William D. Claypool, M.D.; Senior Partner at Pennmark Associates, LLC.
Michael Dougherty; President and Chief Executive Officer, Adolor Corporation
Robert J. Glaser; Senior Partner of Pennmark Associates
John R. Leone; Partner, Paul Capital Partners
Howard H. Pien; Former President, Chief Executive Officer and Director, Medarex

Employees

180 Employees (10/2009)

Ticker

VPHM (Nasdaq Global Select Market)

Our Vision

Our vision at ViroPharma as a multinational pharmaceutical company is to be recognized worldwide for developing and marketing innovative products addressing unmet medical needs. At ViroPharma, we strive to improve the lives of patients and to deliver medicines that address serious unmet medical needs. Our goal is simple in that we dedicate ourselves to developing and marketing products that help address dangerous, potentially life-threatening conditions including diseases such as hereditary angioedema (HAE) that are caused by C1 esterase inhibitor deficiency, and C. difficile. We focus our efforts on providing these medicines to physicians that treat and/or prevent serious diseases, and will expand on those franchises by capitalizing on business development. We will continue to focus on execution in all areas of our business. We will maintain our focus on building shareholder value. We will maintain our focus on the needs of patients, physicians and payers. And we will remain committed to quality and the continuous improvement of our performance, products and people.

Investor Inquiries

Will Roberts; Vice President, Corporate Communications
(610) 321-6288
Robert Doody; Assistant Director, Investor Relations and Corporate Communications
(610) 321-6290

Media Inquiries

Kristina Broadbelt; Assistant Director, Public Relations and Advocacy
(610) 321-2358

Business Development

Clayton Fletcher; Vice President , Business Development
(610) 321-6789
clayton.fletcher@viropharma.com